

Collaborative Working Executive Summary

Project Name

5 Parks Primary Care Network (PCN) Secondary Prevention Service

Between

5 Parks PCN and Recordati Pharmaceuticals Ltd

Project Start

April 2025

Duration

12 Months

Project Summary

5 Parks PCN have identified that a number of their patients, approximately 600, are not currently optimised for Cardiovascular Secondary Prevention in line with the current National Guidelines.

Recordati and 5 Parks PCN have agreed on this collaborative working project so that we can work together to implement a new service to optimise these patients.

The service will use an experienced Pharmacists, supervised by 5 Parks Senior Pharmacists and GP's, to review and optimise the patients across a range of CV risk factors, including blood pressure, LDL Cholesterol and residual CV risk indicated by elevated triglycerides, in with the aim of reducing the patient's risk of a future CV event.

Project Benefits

For Patients

- Improved clinical care for patients, through identification of at-risk Patients and optimising secondary prevention therapies.
- Greater satisfaction of patients due to improved identification and proactive management of their cardiovascular risk through the additional capacity provided by the Secondary Prevention Service.

For 5 Parks PCN

- The Service may lead to reduction in recurrent cardiac events, with eventual medium and long-term saving for NHS and reduction in the downstream burden on the health system (e.g. hospitalisation) from recurrent cardiac events.
- The Service may lead to an increase in the number of patients achieving the Quality and Outcomes (QoF) framework targets for cardiovascular disease which may increase the QoF points achieved.

For Recordati

- Increase in the appropriate use of medicines aligned with local and national guidance which includes Recordati's product.
- Increase in Patients identified and treated for secondary CVD risk factors, which may be relevant to the Recordati business.
- Increased knowledge about the identification and management of secondary prevention patients especially in relation to lipids.
- Increased knowledge about patient choices and reasons for declining evidence-based treatment options.
- Enhanced Recordati reputation and supporting the Recordati Mantra that "health, and the opportunity to live life to the fullest, is a right, not a privilege."

Financial Contribution

The total cost of this project, including direct and indirect costs, is calculated at £87230.

Recordati's contribution to the project is £54930 (63% of total cost)

5 Parks PCN are covering the cost of premises, blood tests, IT, patient information systems, training and supervision of clinical staff.